Therefore, for HER2‐positive breast cancer patients with brain metastases, if the burden of brain metastases is small and the symptoms are mild, pyrotinib can be used alone and the financial burden of patients can be reduced. This evidence concerns the gene ERBB2 and breast carcinoma.